Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

AbbVie

Eli Lilly

Large-cap pharmaceuticals have enjoyed buying pressure over the last month, delivering outsized gains to investors. And these three stocks have helped lead the charge.

These 3 Large-Cap Pharma Stocks Have Been Red-Hot

The dazzling success of weight-loss drugs in the United States is leading to lower interest rates in Denmark, home of one of their biggest manufacturers, according to the Nordic country's biggest bank.

How soaring demand for Ozempic and Wegovy is altering Denmark's economy

AstraZeneca

Johnson & Johnson

Novartis

Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Novartis (NVS) and AstraZeneca (AZN) are worth retaining in your portfolio.

5 Large Drug Stocks to Watch as New Drug Approvals & M&A Gain Pace

Ozempic is practically flying off the shelves to treat diabetes and obesity. The drug could also be useful in reducing cardiac event risk, per a new study.

Ozempic Just Got Even Better for Novo Nordisk Stock

Pfizer

Eli Lilly has explosive growth potential. Novo Nordisk is worth its premium price tag.

3 Fantastic Stocks to Buy in a New Bull Market

Weight-loss drugs are substantially more expensive in the US than in other comparably large, high-income countries, according to a new analysis from the health policy organization KFF. The analysis compared list prices (ie.

Americans are paying dramatically higher prices for weight-loss drugs like Ozempic, report finds

Prescriptions of weight-loss and diabetes drugs have rocketed this year, giving Novo Nordisk stock and Eli Lilly stock more room to run.

Why This Nugget Of Bad Weight-Loss News Isn't Weighing On Lilly, Novo

Constellation Energy Corp

Celsius Holdings

Many stocks have displayed relative strength in the recent term, providing investors with sizable gains.

3 Buy-Rated Stocks Displaying Notable Price Strength

The results complement the data Novo Nordisk released last week, which found Wegovy slashed the risk of serious heart problems and heart-related death by 20%.

Wegovy could prevent up to 1.5 million heart attacks, strokes over 10 years, study says

Exact Sciences

Growing revenue, an improving bottom line, and exciting opportunities paint a bright future for Exact Sciences. Novo Nordisk is virtually unmatched in the diabetes drug market, with more potential medicines on the way.

Prediction: These 2 Stocks Could Double by 2030

Risk-on sentiment and end of pandemic boom have weighed on healthcare. Health insurers and medical device firms have held up better.

Outlook For Healthcare Sector As Obesity Drugs Gain Popularity

Novo Nordisk (NVO) continues to witness increasing demand for its diabetes and obesity care products like Ozempic, Wegovy and Rybelsus amid rising competition from other pharma bigwigs.

Novo Nordisk (NVO) Rides on Ozempic & Wegovy Amid Rivalry

Novo Nordisk rose on news of encouraging outcomes for its SELECT trial of weight loss drug semaglutide. The Danish pharmaceutical leader also raised its full-year sales and profit outlook after posting strong first-half 2023 results.

Why Novo Nordisk Stock Soared 16% This Week

Novo Nordisk (NVO) is well positioned to outperform the market, as it exhibits above-average growth in financials.

3 Reasons Why Novo Nordisk (NVO) Is a Great Growth Stock

Novo Nordisk (NYSE:NVO) has raised its full-year outlook based on a strong first half of 2023 driven by continued high demand for its popular weight-loss drug Wegovy. The Denmark-headquartered global pharmaceutical company expects its sales for 2023 to be up 27% to 33% from the last year, from its prior guidance range of 24% to 30%.

Novo Nordisk raises full-year outlook as Wegovy sales skyrocketed in 2Q

Novo Nordisk raised its outlook as revenue from its popular weight-loss treatment, Wegovy, skyrocketed.

Novo Nordisk Boosts Guidance as Sales of Weight-Loss Drug Wegovy Soar

Novo Nordisk (NVO) reports weaker-than-expected second-quarter 2023 results, missing both earnings and sales estimates. Management, however, raises 2023 guidance.

Novo Nordisk (NVO) Q2 Earnings and Sales Miss, 2023 View Up

Inversago's drugs use a different approach than most treatments in the obesity and diabetes space.

Novo Nordisk to acquire obesity drug maker Inversago Pharma for up to $1 billion

Novo Nordisk A/S (NVO) Q2 2023 Earnings Conference Call August 10, 2023 7:00 AM ET Company Participants Daniel Bohsen - CVP & Head, IR Lars Jorgensen - President & CEO Camilla Sylvest - EVP, Commercial Strategy & Corporate Affairs Douglas Langa - EVP, North America Operations Martin Lange - EVP, Development Karsten Knudsen - EVP & CFO Conference Call Participants Martin Parkhoi - SEB Richard Parkes - BNP Paribas Exane Emily Field - Barclays Bank Peter Verdult - Citigroup Harry Sephton - Crédit Suisse Peter Welford - Jefferies Sachin Jain - Bank of America Merrill Lynch Richard Vosser - JPMorgan Chase & Co. Kerry Holford - Berenberg Michael Novod - Nordea Markets Michael Leuchten - UBS Florent Cespedes - Societe Generale Michael Nedelcovych - TD Cowen Simon Baker - Redburn Operator Good day, and thank you for standing by. Welcome to the Q2 2023 Novo Nordisk A/S Earnings Conference Call.

Novo Nordisk A/S (NVO) Q2 2023 Earnings Call Transcript

Novo Nordisk stock fell early Thursday after the company reported $8 billion in sales, missing more bullish expectations.

Novo Nordisk Skids As Massive Sales Growth Misses Even More Bullish Forecasts

Novo Nordisk hopes to show additional health benefits from taking its hugely popular drug Wegovy, apart from losing weight and cutting the risk of heart disease, its drug development executive told Reuters on Thursday.

Novo eyes other health benefits from weight-loss drug Wegovy after major trial

Novo Nordisk expects new data showing the heart benefits of its weight-loss drug Wegovy will help its discussions with public health authorities and other payers about the benefits of paying for it, executives said on Thursday.

Novo Nordisk: weight-loss Wegovy drug's heart benefits will help discussions with payers

Bagsværd, Denmark and Montreal, Canada, 1 0 August 2023 – Novo Nordisk A/S and Inversago Pharma today announced that Novo Nordisk has agreed to acquire Inversago for up to 1.075 billion US dollars in cash if certain development and commercial milestones are achieved. Inversago Pharma is a private, Montreal-based developer of CB1 receptor-based therapies for the potential treatment of obesity, diabetes and complications associated with metabolic disorders.

Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases

Novo Nordisk's limits on U.S. supplies of starter doses of its hugely popular Wegovy weight-loss drug will likely last into next year, CEO Lars Fruergaard Jorgensen told Reuters on Thursday.

Novo Nordisk's limits on Wegovy US supply seen into 2024, CEO says

Danish drug maker Novo Nordisk said on Thursday it would acquire Canadian company Inversago Pharma in a $1.07 billion deal including the development of an appetite regulator.

News for Novo Nordisk Stock (NVO)